Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CCR4-NOT transcription complex subunit 1 (CNOT1) is the largest subunit of the conserved CCR4-NOT complex, acting as a central scaffolding protein that assembles and stabilizes the other subunits of this multi-protein complex[1][2][3][6]. CNOT1 itself does not have enzymatic or receptor activity, but is essential for deadenylase activity and mRNA decay by recruiting deadenylase modules, such as CNOT7/8 and CNOT6/6L, which are responsible for shortening the poly(A) tails of mRNAs, a key step in regulated mRNA turnover[1][3][6]. CNOT1 also regulates transcription, including by repressing ligand-dependent nuclear receptor signaling (such as estrogen receptor alpha and retinoid X receptor), and interacts with specific RNA-binding proteins to direct mRNA specificity under physiological and developmental contexts[1][5]. CNOT1 is requisite for cellular homeostasis; its depletion destabilizes the entire CCR4-NOT complex and can lead to apoptosis, developmental defects, and deregulation of genes involved in cell proliferation and cancer[1][5].\n\nNote:\n- CNOT1 is not a receptor, enzyme, or transporter itself; it is not a direct drug target, but rather a scaffolding and regulatory component of a major gene expression control complex[1][2][3][6].\n- There are currently no clinically used drugs or known small-molecule modulators that directly target CNOT1; reported disease roles are primarily due to dysregulation or aberrant function within the complex, especially in cancer and cell fate determination[1][5].\n- CNOT1 may serve as a platform for regulatory protein interactions, and its loss or mutation affects mRNA stability and gene expression critical in disease states[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CCR4-NOT transcription complex subunit 1 (CNOT1).